Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease

Biogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but with elevated levels of amyloid in their brains, the protein aggregate that is thought to cause the disease.